NovaBridge Biosciences (NBP) Operating Income (2019 - 2025)

NovaBridge Biosciences (NBP) has reported Operating Income for 5 consecutive years, with -$72.9 million the latest figure, recorded in Q4 2025.

• Quarterly Operating Income fell 445.21% year-over-year to -$72.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$94.3 million (down 83.31% YoY) and the FY2025 annual result came in at -$94.3 million, down 83.31% from the prior year.
• Operating Income declined to -$72.9 million in Q4 2025 per NBP's latest filing, from -$9.0 million in the prior quarter.
• Over the last five years, Operating Income for NBP reached as high as -$5.3 million in Q1 2025 and fell as low as -$72.9 million in Q4 2025.
• A 3-year average of -$18.9 million and a median of -$12.0 million in 2023 frame the typical range for Operating Income.
• Annual changes were most pronounced in 2024 — Operating Income soared 66.12% — and 2025, when it slumped 445.21%.
• Year by year, Operating Income stood at -$39.5 million in 2023, then surged by 66.12% to -$13.4 million in 2024, then sank by 445.21% to -$72.9 million in 2025.
• According to Business Quant data, Operating Income over the past three periods registered -$72.9 million, -$9.0 million, and -$7.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.